GeneDx Holdings Corp.
WGS
$107.20
-$1.15-1.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.76% | 40.35% | 70.60% | 49.01% | 48.90% |
| Total Other Revenue | 166.88% | 2.88% | -34.48% | -140.36% | -48.09% |
| Total Revenue | 45.63% | 39.56% | 66.57% | 44.22% | 44.77% |
| Cost of Revenue | 15.34% | 14.73% | 10.39% | 0.11% | -7.93% |
| Gross Profit | 65.07% | 56.11% | 115.27% | 96.88% | 128.83% |
| SG&A Expenses | 9.93% | 27.71% | 11.58% | 0.72% | -18.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 14.26% | -56.52% | -- |
| Total Operating Expenses | 15.59% | 20.56% | 12.93% | -3.74% | -19.16% |
| Operating Income | 184.70% | 66.57% | 158.44% | 77.55% | 79.50% |
| Income Before Tax | 135.97% | 70.07% | 120.68% | 80.31% | 37.41% |
| Income Tax Expenses | -29.47% | 645.12% | 94.16% | 72.67% | 3.06% |
| Earnings from Continuing Operations | 137.05% | 67.74% | 121.10% | 80.34% | 37.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 137.05% | 67.74% | 121.10% | 80.34% | 37.56% |
| EBIT | 184.70% | 66.57% | 158.44% | 77.55% | 79.50% |
| EBITDA | 382.62% | 113.47% | 287.67% | 92.89% | 87.01% |
| EPS Basic | 134.51% | 70.13% | 119.68% | 81.29% | 40.37% |
| Normalized Basic EPS | 136.36% | 72.23% | 206.80% | 76.00% | 44.24% |
| EPS Diluted | 132.73% | 70.13% | 119.68% | 81.29% | 40.15% |
| Normalized Diluted EPS | 134.92% | 72.23% | 206.80% | 76.00% | 44.24% |
| Average Basic Shares Outstanding | 7.37% | 8.00% | 7.20% | 5.07% | 4.72% |
| Average Diluted Shares Outstanding | 11.78% | 8.00% | 7.20% | 5.07% | 4.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |